ArticleRenal failure2026
Comprehensive trends in Chronic Kidney Disease prevalence and comorbidities across eGFR and albuminuria categories: a 20-year analysis of NHANES data.
Article in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) represents a major public health challenge, contributing to over 1.2 million global deaths annually and ranking as the 12th leading cause of mortality. This study provides a 20-year trend analysis (1999-2018) of CKD prevalence and its associated comorbidities among adults in the United States using the NHANES dataset. Employing the CKD-EPI 2021 equation without the race component, the study revealed a stable CKD prevalence of 20% in adults aged ≥20 years, alongside trends in nine comorbidities. Obesity and diabetes showed significant increases, while hypertension, anemia, hyperkalemia, and cardiovascular disease remained stable. Hypertriglyceridemia and hypercholesterolemia exhibited an initial rise followed by a plateau. The analysis highlights the uneven distribution of CKD comorbidities across KDIGO-defined eGFR and albuminuria subcategories, with G3bA2 and G4A1 patients at heightened risk. These findings underscore the importance of targeted interventions through an individualized care strategy that considers CKD risk category and the comorbidities profiles. Additionally, it offers pivotal epidemiological insights to inform clinical research, policymaking, and precision medicine in nephrology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.